Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: Role of AGE-RAGE signalling

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 3, 2010, Pages 212-222

  Jing, Yu Hong ^a,b   Chen, Kuan Hsing ^a   Yang, Shu Han ^a   Kuo, Pei Ching ^a   Chen, Jan Kan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b LANZHOU UNIVERSITY   (China)

Author keywords

Advanced glycation end product; Diabetes; Receptor for AGE

Indexed keywords

COLLAGEN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL WALL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; STREPTOZOCIN DIABETES; VASCULAR SMOOTH MUSCLE;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; BLOOD GLUCOSE; BLOTTING, WESTERN; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMUNOHISTOCHEMISTRY; INSULIN; MALE; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; STILBENES;

EID: 77952375084     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1076     Document Type: Article

References (53)

1. Third report of the national cholesterol education program (ncep). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation 2002; 106: 3143-3421.
2. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59: 750-755. (Pubitemid 17061281)
3. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.
4. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-234.
5. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
6. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454.
7. Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006; 212: 167-178.
8. Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of nadph oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase c-alpha-dependent pathway. Diabetes 2008; 57: 460-469.
9. Thornalley PJ, Langborg A, Minhas HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344(Pt 1): 109-116.
10. Yu Y, Thorpe SR, Jenkins AJ, et al. Advanced glycation endproducts and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia 2006; 49: 2488-2498. (Pubitemid 44359112)
11. Cipollone F, Iezzi A, Fazia M, et al. The receptor rage as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003; 108: 1070-1077. (Pubitemid 37071516)
12. Reddy GK: Age-related cross-linking of collagen is associated with aortic wall matrix stiffness in the pathogenesis of drug-induced diabetes in rats. Microvasc Res 2004; 68: 132-142.
13. Stitt AW, He C, Friedman S, et al. Elevated age-modified apob in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue ages. Mol Med 1997; 3: 617-627. (Pubitemid 27465233)
14. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003; 21: 3-12.
15. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-1152.
16. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34: 1563-1574.
17. Tan AL, Forbes JM, Cooper ME: Age, rage, and ros in diabetic nephropathy. Semin Nephrol 2007; 27: 130-143.
18. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of nadph oxidase by age links oxidant stress to altered gene expression via rage. AmJ Physiol Endocrinol Metab 2001; 280: E685-E694. (Pubitemid 32466835)
19. Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor rage as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955.
20. Li J, Schmidt AM. Characterization and functional analysis of the promoter of rage, the receptor for advanced glycation end products. J Biol Chem 1997; 272: 16498-16506. (Pubitemid 27276477)
21. Hudson BI, Wendt T, Bucciarelli LG, et al. Diabetic vascular disease: It's all the rage. Antioxid Redox Signal 2005; 7: 1588-1600. (Pubitemid 41767994)
22. Soro-Paavonen A, Watson AM, Li J, et al. Receptor for advanced glycation end products (rage) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008; 57: 2461-2469.
23. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605. (Pubitemid 44199649)
24. Lin L. Rage on the toll road? Cell Mol Immunol 2006; 3: 351-358.
25. Gao X, Zhang H, Schmidt AM, Zhang C. Age/rage produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2008; 295: H491-H498.
26. Jandeleit-Dahm K, Watson A, Soro-Paavonen A. The age/rage axis in diabetes-accelerated atherosclerosis. Clin Exp Pharmacol Physiol 2008; 35: 329-334.
27. Pinent M, Blay M, Blade MC, Salvado MJ, Arola L, Ardevol A. Grape seed-derived procyanidins have an antihyperglycemic effect in streptozotocin-induced diabetic rats and insulinomimetic activity in insulin-sensitive cell lines. Endocrinology 2004; 145: 4985-4990. (Pubitemid 39551116)
28. Yamabe N, Kang KS, Matsuo Y, Tanaka T, Yokozawa T. Identification of antidiabetic effect of iridoid glycosides and low molecular weight polyphenol fractions of corni fructus, a constituent of hachimi-jio-gan, in streptozotocin-induced diabetic rats. Biol Pharm Bull 2007; 30: 1289-1296. (Pubitemid 47037654)
29. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
30. Bordone L, Guarente L. Calorie restriction, sirt1 and metabolism: Understanding longevity. Nat Rev Mol Cell Biol 2005; 6: 298-305. (Pubitemid 40516896)
31. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-220. (Pubitemid 127696281)
32. Olas B, Wachowicz B, Tomczak A, Erler J, Stochmal A, Oleszek W. Comparative anti-platelet and antioxidant properties of polyphenol-rich extracts from: berries of aronia melanocarpa, seeds of grape and bark of yucca schidigera in vitro. Platelets 2008; 19: 70-77. (Pubitemid 351171558)
33. Barger JL, Kayo T, Vann JM, et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 2008; 3: e2264.
34. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-342.
35. Palsamy P, Subramanian S. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother 2008; 62: 598-605.
36. Thirunavukkarasu M, Penumathsa SV, Koneru S, et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007; 43: 720-729. (Pubitemid 47102122)
37. Su HC, Hung LM, Chen JK. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2006; 290: E1339-E1346.
38. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984; 81: 583-587. (Pubitemid 14186609)
39. Lawson SR, Gabra BH, Guerin B, et al. Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in wistar rats: Blockade with a selective bradykinin b1 receptor antagonist. Regul Pept 2005; 124: 221-224. (Pubitemid 39488363)
40. Palsamy P, Subramanian S. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem Biol Interact 2009; 179: 356-362.
41. Zang M, Xu S, Maitland-Toolan KA, et al. Polyphenols stimulate amp-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic ldl receptor-deficient mice. Diabetes 2006; 55: 2180-2191.
42. Um JH, Park SJ, Kang H, et al. Ampk-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59: 554-563.
43. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappab. Diabetes 2001; 50: 2792-2808.
44. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897.
45. Poussier B, Cordova AC, Becquemin JP, Sumpio BE. Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. J Vasc Surg 2005; 42: 1190-1197.
46. El-Mowafy AM, Alkhalaf M, El-Kashef HA. Resveratrol reverses hydrogen peroxide-induced proliferative effects in human coronary smooth muscle cells: a novel signaling mechanism. Arch Med Res 2008; 39: 155-161. (Pubitemid 350299627)
47. Bierhaus A, Illmer T, Kasper M, et al. Advanced glycation end product (age)-mediated induction of tissue factor in cultured endothelial cells is dependent on rage. Circulation 1997; 96: 2262-2271. (Pubitemid 27425832)
48. Cai W, He JC, Zhu L, et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased ager1 expression. Am J Pathol 2007; 170: 1893-1902. (Pubitemid 47339263)
49. Lin RY, Choudhury RP, Cai W, et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein e-deficient mice. Atherosclerosis 2003; 168: 213-220. (Pubitemid 36703319)
50. Cai W, He JC, Zhu L, et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004; 110: 285-291. (Pubitemid 38955497)
51. Corman B, Duriez M, Poitevin P, et al. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci USA 1998; 95: 1301-1306. (Pubitemid 28124953)
52. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104: 1464-1470. (Pubitemid 32917336)
53. Susic D, Varagic J, Ahn J, Frohlich ED. Crosslink breakers: a new approach to cardiovascular therapy. Curr Opin Cardiol 2004; 19: 336-340.